Regenxbio's Gene Therapy Outlook Dims As Rival Treatments Gain Ground, Goldman Sachs Warns
Goldman Sachs downgraded Regenxbio Inc (NASDAQ:RGNX), citing gene therapy’s appeal for wet AMD and diabetic retinopathy is ...
Class Action Filed Against Regeneron Pharmaceuticals, Inc. (REGN) Seeking Recovery for Investors – Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / February 11, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...
Guggenheim lowers Regeneron price target, says selloff ‘overdone’
Guggenheim lowered the firm’s price target on Regeneron (REGN) to $950 from $1,200 and keeps a Buy rating on the shares. The firm, which is ...
Hosted on MSN23h
Biogen Gears Up to Report Q4 Earnings: What's in the Cards?
Biogen BIIB will report fourth-quarter and full-year 2024 results on Feb. 12, before market open. In the last reported ...
Cepham Introduces Life Phases and Stages Blends For the Next Evolution in Personalized Nutrition
Cepham, a leader in nutraceutical innovation, has introduced its Life Phases and Stages Blends (LPAS Blends), a new line of scientifically formulated ingredient blends designed to address nutritional ...